Rezolute, Inc.
About Rezolute, Inc.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$74.4M
- Total assets
- $175.5M
- Market cap
- $409.2M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $79.9M
- Operating income
- -$79.9M
- Income tax
- $0
- Net income
- -$74.4M
- EPS (basic)
- $-0.98
- EPS (diluted)
- $-0.98
Balance sheet
- Total assets
- $175.5M
- Current assets
- $171.1M
- Total liabilities
- $13.4M
- Current liabilities
- $11.9M
- Shareholders’ equity
- $162.1M
Cash flow
- Operating cash flow
- -$69.1M
- Investing cash flow
- -$14.5M
- Financing cash flow
- $107.3M
- Net cash flow
- $23.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $409.2M
- EPS (diluted)
- $-0.98
- Shares outstanding
- 100.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 23, 2011
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $74.4M.
- Trading 63% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Rezolute, Inc..
Write a review
News about Rezolute, Inc.
News & sentiment via Polygon.io
